Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD5L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD5L Recombinant Protein (ECD-Fc / His-Tag) HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled (<1 EU/μg), Sequence Verified. |
View CD5L Products |
| Gene Delivery | CD5L Lentivirus Premade Particles / Promise-ORF Full-length ORF for stable cell line construction and overexpression. |
View CD5L Products |
| Benchmark Ab | Anti-CD5L Recombinant Antibody High-affinity positive control for functional blocking and binding assays. |
View CD5L Products |
| Validator | CD5L siRNA Set Target-specific knockdown verification in primary macrophages or cell lines. |
View CD5L Products |
| Related Target A | CD36 Primary scavenger receptor interacting with CD5L to regulate lipid uptake and apoptosis. |
View CD36 Products |
| Related Target B | CD5 Homologous scavenger receptor cysteine-rich (SRCR) family member for cross-reactivity and selectivity screening. |
View CD5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Epitope Specificity & Homologue Off-Targeting | Native glycosylation preserved via HEK293 expression; strict mass spectrometry verification to prevent cross-reactivity with CD5 or CD6. |
| Inconsistent Receptor Binding (CD36/TLR4) | High-purity, monomeric CD5L protein with verified theoretical molecular weight and low endotoxin levels to avoid non-specific TLR activation. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included for assay standardization. |
| False Positives in Knockdown Studies | Sequence-specific siRNA sets included for robust target validation and phenotypic verification. |
Live CD5L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD5L therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-functional biologics and targeted metabolic therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting CD5L's role as a dual regulator of lipid metabolism and macrophage-mediated inflammatory responses. Originally identified as an apoptosis inhibitor of macrophages (AIM), CD5L is now recognized as a critical therapeutic target in Non-Alcoholic Steatohepatitis (NASH/MASH), liver fibrosis, and oncology, where it modulates the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Neutralizing) | Academic Institutes, Biopharma Startups | Liver Fibrosis, Autoimmune Diseases, NASH | Blocking Assay (Requires highly stable, HEK293-expressed CD5L to mimic native receptor binding) |
| Recombinant Protein Therapy | Toray Industries, Metabolic Research Consortia | Acute Kidney Injury (AKI), Obesity, NASH | Pharmacokinetic (PK) standards and target validation (Requires high purity >95% and endotoxin-controlled proteins) |
| Combination Therapies (Anti-CD5L + Anti-CD36) | Oncology and Immunology Pioneers | Hepatocellular Carcinoma (HCC), Solid Tumors | Synergy & Receptor Interaction Assays (Requires co-incubation with validated CD36 target proteins) |